about
Management of endocrine disease: Secondary osteoporosis: pathophysiology and managementRisk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study.Risk of fractures in patients with multiple sclerosis: record-linkage studyThe association between multiple sclerosis and fracture riskBMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis.Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study.Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis.Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosisDisease-specific perception of fracture risk and incident fracture rates: GLOW cohort study.Bone health and multiple sclerosis.Vitamin D in multiple sclerosis: implications for assessment and treatment.Multiple sclerosis and fracture.Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.The risk of fracture in incident multiple sclerosis patients: the Danish National Health Registers.Vitamin D receptor Bsm1 polymorphism, calcium metabolism and bone mineral density in patients with multiple sclerosis: a pilot study.Genetic Polymorphism of miR-196a-2 is Associated with Bone Mineral Density (BMD).Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D
P2860
Q26998249-8E4B68C9-9EC3-474D-B9F6-140A3D6A7935Q30248491-04006E5F-A2AA-4A2F-8C49-58B632166695Q34429852-38D87332-91F6-431E-9853-2B96F7E007CAQ34466823-AD9FD5F4-2440-49BE-93B6-0F7252AB5FE0Q34769993-441DE5A6-5BFF-4D9E-A0B0-B9983D93463DQ35431911-31A36EA8-7F5D-46BE-9864-B12261DAA18AQ36213665-650ABF19-B911-48B7-93CB-7C21EABA7B36Q36591035-5FE6E0FC-ED80-4C54-9CC1-7A857EB661EBQ36638670-D1A3BA7E-6CA6-45BA-93A1-D3511D6C386CQ37401906-CF67D612-0E66-4CA1-A249-CF0F6A6D2127Q38022220-C2A11BA2-37F6-47FC-BF9B-E93079BB13F6Q38049627-F53BF2C5-1971-40DD-952E-E9A481F0D605Q38091129-83F9B5AA-AD57-4593-85AF-02AD3560DE82Q38215692-1E847E31-0690-45BB-B94E-C062E1B0475DQ38433457-90FB0BB1-65F9-42B7-8713-0BC146ADB975Q43833035-2B29F076-1236-4BB1-87FC-0749491A7AD2Q47396541-59302C95-B5CC-4A3F-8954-C3DCD2CC13F4Q58711745-09C40AAF-BD20-430C-A80C-F4CD26DC2F5F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone health in multiple sclerosis.
@en
Bone health in multiple sclerosis.
@nl
type
label
Bone health in multiple sclerosis.
@en
Bone health in multiple sclerosis.
@nl
prefLabel
Bone health in multiple sclerosis.
@en
Bone health in multiple sclerosis.
@nl
P2860
P1476
Bone health in multiple sclerosis.
@en
P2093
G D Summers
J C Gibson
P2860
P2888
P304
P356
10.1007/S00198-011-1644-8
P407
P577
2011-05-21T00:00:00Z